Zobrazeno 1 - 10
of 141
pro vyhledávání: '"L Van der Poel"'
Autor:
K. Honney, M Kaneshamoorthy, Sarah Hopkins, H Mark, A Balogun, P Athauda, A Halliday, M Vincent, L Van der Poel, Z Fritz, A Jakupaj, D Ondhia, Stephen Barclay, C Pampali
Publikováno v:
Age and Ageing. 49:i30-i32
Introduction When a doctor is informed of a patient’s future care preferences if they were to lose capacity, there is an ethical and legal obligation to share this information with the treating medical team. In frail older patients, conversations a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::743a9fbbb75530b66c0fc4ddc683fe1e
https://doi.org/10.1093/ageing/afz194.02
https://doi.org/10.1093/ageing/afz194.02
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Mart P. Janssen, Cees L. van der Poel, Hans L. Zaaijer, Welling Oei, Mirjam Kretzschmar, Roel A. Coutinho
Publikováno v:
Transfusion. 54:1705-1711
Background The Q fever outbreaks in the Netherlands in 2007 to 2009 initiated discussion on the necessity of measures to prevent transmission through blood products. Risk assessments help transfusion regulators decide when and where measures are requ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::873c9f5af3acfb0f0b469625a62799df
https://doi.org/10.1111/trf.12539
https://doi.org/10.1111/trf.12539
Autor:
Jim E. van Steenbergen, Welling Oei, Sybille Rehmet, Mirjam Kretzschmar, Mart P. Janssen, Cees L. van der Poel
Publikováno v:
Transfusion. 53:1421-1428
BACKGROUND: A timely risk assessment is desired to guide decisions on preventive transfusion safety measures during emerging infectious disease (EID) outbreaks. The European Up-Front Risk Assessment Tool (EUFRAT) model was developed to provide quanti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::799d34562681ebdea60f7b80844d503e
https://doi.org/10.1111/j.1537-2995.2012.03941.x
https://doi.org/10.1111/j.1537-2995.2012.03941.x
Publikováno v:
Transfusion. 52:478-488
BACKGROUND: During the past decade, blood screening tests such as triplex nucleic acid amplification testing (NAT) and human T-cell lymphotropic virus type I or I (HTLV-I/II) antibody testing were added to existing serologic testing for hepatitis B v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b4e1864284085d306ef5f89ea3ae37d
https://doi.org/10.1111/j.1537-2995.2011.03319.x
https://doi.org/10.1111/j.1537-2995.2011.03319.x
Publikováno v:
Transfusion. 50:2455-2460
BACKGROUND: Concerns have been raised that aging of the general population will increase the demand for blood products. Modeling can be applied to assess trends in blood demand and supply and predict how these will develop over time. STUDY DESIGN AND
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a71d7a2b8a7d80efd44c5a706118322
https://doi.org/10.1111/j.1537-2995.2010.02716.x
https://doi.org/10.1111/j.1537-2995.2010.02716.x
Autor:
C. L. Van Der Poel, Gouke J. Bonsel, Mart P. Janssen, W. P. Schaasberg, B. van Hout, B. A. Borkent-Raven
Publikováno v:
Vox Sanguinis. 100:196-203
Background Cost-effectiveness analyses of blood safety interventions require estimates of the life expectancy after blood product transfusion. These are best derived from survival after blood transfusion, per age group and blood component type. Study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66f883e19baee5687eba02d8e056c194
https://doi.org/10.1111/j.1423-0410.2010.01378.x
https://doi.org/10.1111/j.1423-0410.2010.01378.x
Autor:
Mart P. Janssen, B van Hout, Gouke J. Bonsel, B. A. Borkent-Raven, C. L. Van Der Poel, W. P. Schaasberg
Publikováno v:
Vox Sanguinis. 99:54-64
Background Transfusion recipient data are needed for correct estimation of cost-effectiveness in terms of recipient outcomes after transfusion. Also, such data are essential for monitoring blood use, estimation of future blood use and benchmarking. S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::436aa447caf86b25f0da7b327a6397a3
https://doi.org/10.1111/j.1423-0410.2010.01312.x
https://doi.org/10.1111/j.1423-0410.2010.01312.x
Autor:
Eric Cator, B van Hout, Gouke J. Bonsel, C. L. Van Der Poel, W. P. Schaasberg, Mart P. Janssen
Publikováno v:
Vox sanguinis, 96(4), 298-308. Wiley-Blackwell
Vox Sanguinis, 96(4), 298-308. Wiley-Blackwell Publishing Ltd
Vox Sanguinis, 96(4), 298-308. Wiley-Blackwell Publishing Ltd
BACKGROUND AND OBJECTIVES: European legislation requires manufacturers of plasma products to report epidemiological data on human immunodeficiency virus, hepatitis B virus and hepatitis C virus in donor populations. The incidence rates of such infect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ac3b7956ba151ee3790e98cc561da5a
https://doi.org/10.1111/j.1423-0410.2009.01166.x
https://doi.org/10.1111/j.1423-0410.2009.01166.x
Autor:
G.A. de Wit, C. L. Van Der Poel, Gouke J. Bonsel, Mart P. Janssen, B. A. Borkent-Raven, B van Hout
Publikováno v:
Transfusion, 49(2), 311-319. Wiley-Blackwell
Background To further reduce the risk of hepatitis B virus (HBV) transmission by blood transfusion, nucleic acid testing (NAT) can be employed. The aim of this study is to estimate the incremental cost-effectiveness ratio (ICER) in the Netherlands of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96a5b1b2de154bac04f3ae6edcbe1838
https://doi.org/10.1111/j.1537-2995.2008.01968.x
https://doi.org/10.1111/j.1537-2995.2008.01968.x